Data Insights

OnCARlytics by Imugene for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

OnCARlytics is under clinical development by Imugene and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - OnCARlytics in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

OnCARlytics by Imugene for Melanoma: Likelihood of Approval

OnCARlytics is under clinical development by Imugene and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - OnCARlytics in Melanoma

Data Insights

OnCARlytics by Imugene for Breast Cancer: Likelihood of Approval

OnCARlytics is under clinical development by Imugene and currently in Phase I for Breast Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - OnCARlytics in Breast Cancer

Data Insights

OnCARlytics by Imugene for Ovarian Cancer: Likelihood of Approval

OnCARlytics is under clinical development by Imugene and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - OnCARlytics in Ovarian Cancer

Data Insights

Azercabtagene zapreleucel by Imugene for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Azercabtagene zapreleucel by Imugene for Non-Hodgkin Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Non-Hodgkin Lymphoma

Data Insights

VAXINIA by Imugene for Head And Neck Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Head And Neck Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Head And Neck Cancer

Data Insights

VAXINIA by Imugene for Gastric Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Gastric Cancer

Data Insights

VAXINIA by Imugene for Bladder Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Bladder Cancer

Data Insights

VAXINIA by Imugene for Hepatocellular Carcinoma: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Hepatocellular Carcinoma

Data Insights

VAXINIA by Imugene for Solid Tumor: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Solid Tumor

Data Insights

VAXINIA by Imugene for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According to...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Kidney Cancer (Renal Cell Cancer)

Data Insights

VAXINIA by Imugene for Non-Small Cell Lung Cancer: Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Non-Small Cell Lung Cancer

Data Insights

VAXINIA by Imugene for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

VAXINIA by Imugene for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Triple-Negative Breast Cancer (TNBC)

Data Insights

VAXINIA by Imugene for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

VAXINIA is under clinical development by Imugene and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Azercabtagene zapreleucel by Imugene for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...

Data Insights

Azercabtagene zapreleucel by Imugene for Follicular Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Follicular Lymphoma

Data Insights

Azercabtagene zapreleucel by Imugene for Mantle Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Mantle Cell Lymphoma

Data Insights

Azercabtagene zapreleucel by Imugene for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Diffuse Large B-Cell Lymphoma